Drug combo aims to stall head and neck Cancer's return

NCT ID NCT00942734

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This phase 2 trial investigates whether combining two drugs—RAD001 (everolimus) and erlotinib (Tarceva)—can help control recurrent squamous cell carcinoma of the head and neck. The study enrolls adults whose cancer has returned after platinum-based chemotherapy. Participants take both drugs daily in 28-day cycles. The main goal is to see how many patients remain cancer-free or stable after 12 weeks, with safety also monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RAD001 (everolimus) and erlotinib (Tarceva)
What this could lead to
If successful, this combination could offer a new treatment option for patients with recurrent head and neck cancer who have not responded to standard chemotherapy.
What could go wrong
This is an early-phase trial with only 49 participants, so results may not apply broadly. The combination may cause side effects and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.